Across TCGA pan-cancer cohorts, LRRC73 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LRRC73 data layer compared with 30 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher LRRC73 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC73 expression acts as an unfavorable survival marker.

BRCA, DLBC, and MESO are the cancer types where LRRC73 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	II,III,IV	0.106	0.566	<.001	24	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LRRC73 tumor-vs-normal RNA expression · all LRRC73 data types